Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8278164 | 0.89 | BCHE (0.43) | BCHESMN1; SMN2LMNATSHRCYP2C19 | |
| SCHEMBL1509796 | 0.88 | CASP3 (0.43) | BCHESMN1; SMN2LMNAHTR2A | |
| SCHEMBL1509798 | 0.88 | CASP3 (0.43) | BCHESMN1; SMN2LMNAHTR2A | |
| SCHEMBL1857254 | 0.88 | BCHE (0.41) | BCHESMN1; SMN2LMNATSHRACHE | |
| SCHEMBL1509753 | 0.85 | BCHE (0.39) | BCHESMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL1509754 | 0.85 | BCHE (0.39) | BCHESMN1; SMN2LMNATSHRTP53 | |
| SCHEMBL12664613 | 0.83 | CASP3 (0.39) | BCHESMN1; SMN2LMNA | |
| SCHEMBL8354507 | 0.82 | BCHE (0.42) | BCHELMNAACHEMAPT | |
| SCHEMBL8278171 | 0.82 | BCHE (0.42) | BCHELMNAACHEMAPT | |
| SCHEMBL8277396 | 0.82 | CASP3 (0.39) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317454-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2011-05-25 | — | — | EP | disclosed |
| US-6800619-B2 | UREA HETEROCYCLICCARBONYL-SUBSTITUTED ASPARTIC OR GLUTAMIC ACID DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-05 | — | — | US | disclosed |
| EP-1317454-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020058630-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-05-16 | — | — | US | disclosed |
| WO-2002022611-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058630-A1 | Caspase inhibitors and uses thereof | CASP2, CASP3, CASP7 | BCHE 470/4885POLB 4227/4885ATM 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.